EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial

Abhayjit Singh, Luke J Laffin, Ashish Sarraju, A Michael Lincoff, Stephen J Nicholls, LeAnne Bloedon, William J Sasiela, Na Li, Paula Robinson, Stephanie Kelly, Denise Mason, Steven E Nissen

Clinical Cardiology · 2024-08 · 47 (8)

DOI: 10.1002/clc.24328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 30.07.2024. Verfasst von Abhayjit Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, COVID-19, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The CLEAR Outcomes trial was funded by Esperion Therapeutics..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The COVID‐19 pandemic disrupted clinical research. CLEAR Outcomes investigated the effect of bempedoic acid (BA) versus placebo in 13 970 patients with statin intolerance and high cardiovascular (CV) risk. BA reduced the risk of the primary endpoint (composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) by 13%. CLEAR Outcomes began before and continued for 2.7 years after the start of the pandemic.

Methods

The impact of the COVID‐19 pandemic on patient disposition, adverse events, and major adverse CV events (MACE) in CLEAR Outcomes was assessed.

Results

Rates of severe infection, hospitalization, or first MACE associated with a positive COVID‐19 test were low and balanced between treatment groups. Rates of all‐cause death, non‐CV death, and undetermined death increased in the pandemic period compared with the pre‐pandemic period, while rates of CV death with a known etiology remained stable. A sensitivity analysis excluding undetermined deaths occurring after the onset of the pandemic from the CV death designation yielded hazard ratios of 0.84 (95% CI, 0.76–0.93) for the primary endpoint and 0.94 (95% CI, 0.76–1.16) for the secondary endpoint of CV death, compared with 0.87 (95% CI, 0.79–0.96) and 1.04 (95% CI, 0.88–1.24), respectively, in the original analysis.

Conclusion

The CLEAR Outcomes trial continued uninterrupted throughout the COVID‐19 pandemic. Certain trial endpoints may have been impacted by the pandemic. Specifically, the classification of undetermined deaths as CV deaths may have attenuated the effect of BA on key efficacy endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesCOVID-19Randomized Controlled Trials as TopicAgedFemaleHumansMaleMiddle AgedHydroxymethylglutaryl-CoA Reductase InhibitorsPandemicsSARS-CoV-2Treatment Outcome

Stichwörter der Autor:innen

COVID‐19bempedoic acidcardiovascular outcomesclinical trialhyperlipidemiastatin intolerance

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, Ohio, USA.
  • Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
  • Esperion Therapeutics Inc., Ann Arbor, Michigan, USA.

Förderung

  • The CLEAR Outcomes trial was funded by Esperion Therapeutics.

Zitieren

APA

Singh, A., Laffin, L. J., Sarraju, A., Michael Lincoff, A., Nicholls, S. J., Bloedon, L., Sasiela, W. J., Li, N., Robinson, P., Kelly, S., Mason, D., & Nissen, S. E. (2024). Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial. Clinical Cardiology, 47(8). https://doi.org/10.1002/clc.24328

Vancouver

Singh A, Laffin LJ, Sarraju A, Michael Lincoff A, Nicholls SJ, Bloedon L, et al. Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial. Clinical Cardiology. 2024;47(8). doi:10.1002/clc.24328

BibTeX
@article{Singh2024,
  author = {Singh, Abhayjit and Laffin, Luke J and Sarraju, Ashish and Michael Lincoff, A and Nicholls, Stephen J and Bloedon, LeAnne and Sasiela, William J and Li, Na and Robinson, Paula and Kelly, Stephanie and Mason, Denise and Nissen, Steven E},
  title = {Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial},
  journal = {Clinical Cardiology},
  year = {2024},
  volume = {47},
  number = {8},
  doi = {10.1002/clc.24328}
}
Kostenlos starten →